

IMEZEMIC

Imeglimin Hydrochloride 500 / 1000 mg Tablets




IMEZEMIC-SR

Imeglimin Hydrochloride (SR) 1000 mg Tablets



**Address the deep rooted
Mitochondrial Dysfunction**



IMEZEMIC

Imeglimin Hydrochloride 500 / 1000 mg Tablets

IMEZEMIC-SR

Imeglimin Hydrochloride (SR) 1000 mg Tablets

BACKGROUND:


Type 2 diabetes (T2D) is one of the most common chronic diseases, characterized by pancreatic β -cell dysfunction and insulin resistance leading to chronic hyperglycemia. Unmet medical needs are still a reality in T2D and new medications with sustained efficacy and a good tolerability profile are still required. Glimins are the new category for the management of T2DM. Imeglimin is a first-in-class oral antidiabetic drug used to treat T2D targeting mitochondrial bioenergetics.

INDICATION:

Imeglimin is a first-in-class drug with a unique dual mechanism of action for the treatment of Type 2 Diabetes.

MECHANISM OF ACTION:

Imeglimin is an orally administered, first-in-class glimin. Glimins are a novel class of glucose lowering agent that target multiple components of diabetes associated pathology by:



DOSAGE AND ADMINISTRATION:

For adults, The recommended dosing range of Imeglimin hydrochloride is 1000 - 2000 mg in divided doses or as directed by the Physician.

USP:

Unique MOA offers the potential opportunity for Imeglimin to be a candidate for the treatment of type 2 diabetes in almost all stages of the current anti-diabetic treatment paradigm, including monotherapy or as an add-on to other glucose lowering therapies.

References:

1. DIABETES CARE, VOLUME 36, MARCH 2013
2. Diabetes Obes Metab.2021;23:664-673.
3. Diabetes Care 2021;44(4):952-959

Scan for more Prescribing Information



La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: +91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2024 All rights reserved, La Renon Healthcare Private Limited